Pages that link to "Q33674134"

The following pages link to The impact of population based screening for carriers of cystic fibrosis (Q33674134):

Displaying 42 items.

• Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Q24187920) (← links)
• Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease (Q24202057) (← links)
• Genetic testing in asymptomatic minors: background considerations towards ESHG Recommendations (Q24599256) (← links)
• Attitudes toward genetic testing among the general population and relatives of patients with a severe genetic disease: a survey from Finland. (Q30233863) (← links)
• Realising the potential of the family history in risk assessment and primary prevention of coronary heart disease in primary care: ADDFAM study protocol (Q33509900) (← links)
• Attitudes towards bipolar disorder and predictive genetic testing among patients and providers (Q33677520) (← links)
• Knowledge, attitudes, and barriers to carrier screening for the Ashkenazi Jewish panel: a Florida experience : Education and Barriers assessment for Jewish Genetic Diseases (Q33764090) (← links)
• Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group (Q34175545) (← links)
• Evaluation of cystic fibrosis carrier screening programs according to genetic screening criteria (Q34781236) (← links)
• Preconceptional genetic carrier testing and the commercial offer directly-to-consumers (Q34815598) (← links)
• Social and psychological issues associated with the new genetics (Q35211643) (← links)
• PCR-based screening for cystic fibrosis carrier mutations in an ethnically diverse pregnant population. (Q35238673) (← links)
• Carrier testing of children for two X linked diseases in a family based setting: a retrospective long term psychosocial evaluation (Q35571101) (← links)
• Implications of carrier identification in newborn screening for cystic fibrosis (Q35571693) (← links)
• Teaching about cystic fibrosis carrier screening by using written and video information (Q35643539) (← links)
• Cystic fibrosis heterozygote screening in 5,161 pregnant women (Q35881825) (← links)
• Cystic fibrosis carrier population screening in the primary care setting (Q35882814) (← links)
• Carrier screening in preconception consultation in primary care (Q36164703) (← links)
• Attitudes of health care professionals toward carrier screening for cystic fibrosis. A review of the literature. (Q37471817) (← links)
• Can we make assumptions about the psychosocial impact of living as a carrier, based on studies assessing the effects of carrier testing? (Q37794052) (← links)
• Population-based carrier screening for cystic fibrosis: a systematic review of 23 years of research. (Q38136985) (← links)
• Genetic advances in cystic fibrosis: to screen, to treat or both? (Q38477273) (← links)
• Update and Review: Cystic Fibrosis (Q38542676) (← links)
• A randomized controlled trial to assess the psychological impact of a family history screening questionnaire in general practice (Q40731077) (← links)
• Economic evaluation of diagnostic technology. Methodological challenges and viable solutions. (Q41715681) (← links)
• Psychosocial Responses to being Identified as a Balanced Chromosomal Translocation Carrier: a Qualitative Investigation of Parents in Japan (Q47729792) (← links)
• Women's attitudes toward testing for fragile X carrier status: a qualitative analysis (Q48480087) (← links)
• Three-month follow-up of Western and non-Western participants in a study on preconceptional ancestry-based carrier couple screening for cystic fibrosis and hemoglobinopathies in the Netherlands (Q50772316) (← links)
• Gender differences in psychosocial reactions to cystic fibrosis carrier testing (Q51036260) (← links)
• Carrier screening for cystic fibrosis: test acceptance and one year follow-up (Q51099576) (← links)
• Psychological impact of population-based carrier testing for cystic fibrosis: 3-year follow-up. UK Cystic Fibrosis Follow-Up Study Group (Q51113989) (← links)
• Distress and psychosocial needs of a heterogeneous high risk familial cancer population. (Q51472887) (← links)
• Psychological adjustment and knowledge about hereditary hemochromatosis in a clinic-based sample: a prospective study. (Q51922759) (← links)
• Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. (Q52656492) (← links)
• Outcomes of Counseling after Education about Carrier Results: A Randomized Controlled Trial. (Q53437001) (← links)
• Population screening for cystic fibrosis: A research agenda for the next 10 years (Q57745594) (← links)
• Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk (Q73144997) (← links)
• Risk perception after CF carrier testing and impact of the test result on reproductive decision making (Q73212932) (← links)
• Prenatal screening for cystic fibrosis carriers: does the method of testing affect the longer-term understanding and reproductive behaviour of women? (Q73745479) (← links)
• Possibilities and barriers in the implementation of a preconceptional screening programme for cystic fibrosis carriers: a focus group study (Q79106322) (← links)
• Attitudes of potential providers towards preconceptional cystic fibrosis carrier screening (Q84531991) (← links)
• Counseling and screening for cystic fibrosis in patients with congenital bilateral absence of the vas deferens: Patient perceptions (Q86745741) (← links)